For filings with the FCA include the annex
For filings with issuer exclude the annex
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii
Bioventix PLC
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights
X
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):
3. Full name of person(s) subject to the notification obligation: iii
Wasatch Advisors, Inc.
4. Full name of shareholder(s)
(if different from 3.):iv
Wasatch World Innovators Fund
5. Date of the transaction and date on which the threshold is crossed or reached: v
December 28, 2016
6. Date on which issuer notified:
December 29, 2016
7. Threshold(s) that is/are crossed or reached: vi,vii
3%
8. Notified details:
A: Voting rights attached to shares viii,ix
Class/type of shares
if possible using the ISIN CODE
Situation previous to the triggering transaction
Resulting situation after the triggering transaction
Number of Shares
Number of Voting Rights
Number of shares
Number of voting rights
% of voting rights x
Direct
Direct xi
Indirect xii
Direct
Indirect
GB00B4QVDF07
153,850
153,850
151,350
151,350
2.99%
B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial
Expiration
Exercise/
Number of voting
% of voting
instrument
date xiii
Conversion Period xiv
rights that may be
rights
acquired if the
instrument is
exercised/ converted.
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments
xv, xvi
Resulting situation after the triggering transaction
Type of financial instrument
Exercise price
Expiration datexvii
Exercise/ Conversion period xviii
Number of voting rights instrument refers to
% of voting rights xix,xx
Nominal
Delta
Total (A+B+C)
Number of voting rights
Percentage of voting rights
151,350
2.99%
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi
Proxy Voting:
10. Name of the proxy holder:
11. Number of voting rights proxy holder will cease to hold:
12. Date on which proxy holder will cease to hold voting rights:
13. Additional information:
14. Contact name:
Wasatch Advisors, Inc.
Rebekah Gold Sr. Compliance Associate
15. Contact telephone number:
(801) 533-0777
Bioventix plc published this content on 05 January 2017 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 09 January 2017 16:23:08 UTC.
Original documenthttp://www.bioventix.com/index_htm_files/RNS05012017.pdf
Public permalinkhttp://www.publicnow.com/view/45B930556740C1A547517A09FEC992808188EFC3
Bioventix plc is a United Kingdom-based company specializing in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at the Company are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. It offers a portfolio of antibodies to customers for both commercial use and research and development purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function, and drug abuse. The Companyâs products include sheep monoclonal antibodies (SMAs), Pyrene (HOP-G) ELISA Kits, and Pyrene (HOP-G) Lateral Flow Kits. The Company supplies antibody products and services to the majority of multinational clinical diagnostics companies.